Document Type
Article
Version Deposited
Published Version
Publication Date
9-1-2024
Publication Title
Skin Research and Technology
DOI
10.1111/srt.70041
Abstract
INTRODUCTION: Psoriasis is an immune-mediated inflammatory skin disease. First-line topical treatments include steroids, calcineurin inhibitors, vitamin D analogs, and anthralin. Recently, novel topical therapeutics like tapinarof and roflumilast have emerged with unique anti-inflammatory mechanisms and promising efficacy profiles.
MATERIALS AND METHODS: This review utilized PubMed, SCOPUS, and Web of Science databases to identify recent studies on tapinarof and roflumilast. Criteria focused on efficacy, safety profiles, and therapeutic roles in psoriasis treatment.
RESULTS: Four primary literature articles were identified for tapinarof and five for roflumilast. Both drugs demonstrated strong efficacy with minimal adverse events in treating mild-to-moderate plaque psoriasis. Tapinarof showed more frequent but mild adverse effects, while roflumilast had less frequent but more severe side effects.
DISCUSSION: Tapinarof and roflumilast offer once-daily dosing and successful treatment in restricted areas, potentially enhancing patient adherence. Cost remains a limiting factor, necessitating future comparative studies to evaluate the efficacy, safety, and cost-effectiveness between the two drugs.
CONCLUSION: Tapinarof and roflumilast present promising topical treatments for psoriasis, showing efficacy and manageable safety profiles. Further research is crucial to fully elucidate their comparative benefits and drawbacks in clinical practice.
Recommended Citation
Ghani, Hira; Podwojniak, Alicia; Tan, Isabella J; Parikh, Aarushi K; Sanabria, Bianca; and Rao, Babar, "A Comparison of the Safety and Efficacy of Tapinarof and Roflumilast Topical Therapies in the Management of Mild-to-Moderate Plaque Psoriasis" (2024). Rowan-Virtua School of Osteopathic Medicine Departmental Research. 225.
https://rdw.rowan.edu/som_facpub/225
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Published Citation
Ghani H, Podwojniak A, Tan IJ, Parikh AK, Sanabria B, Rao B. A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild-to-moderate plaque psoriasis. Skin Res Technol. 2024 Sep;30(9):e70041. doi: 10.1111/srt.70041. PMID: 39206797; PMCID: PMC11359094.
Included in
Dermatology Commons, Pathological Conditions, Signs and Symptoms Commons, Pharmaceutical Preparations Commons, Skin and Connective Tissue Diseases Commons, Therapeutics Commons
